Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review.

Cureus · 2023 · PMC10639032 · PMID 37954768

Europe PMC DOI

hedged sentence

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

a favorable trendP = 0.095so close (0.05 < p ≤ 0.1)

In comparison to placebo, pioglitazone was linked with a favorable trend for macrovascular endpoints (19.7% vs. 21.7%; HR = 0.90, 95%CI 0.80-1.02, P = 0.095) [ 13 ].

also in 313 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.